Conifer to lay off over 1,000 workers
The layoffs come months after CommonSpirit announced it was ending its service contract early and exiting its stake in the Tenet-owned revenue cycle company.
The layoffs come months after CommonSpirit announced it was ending its service contract early and exiting its stake in the Tenet-owned revenue cycle company.
BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new findings for their closely watched programs, highlighting overall survival benefits in various types of lung cancer.
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs Read More »
The separation will allow Medtronic to focus on its cardiovascular, neuroscience and surgical portfolios, CEO Geoff Martha said.
Medtronic begins final steps to separate MiniMed Read More »
Reducing headcount at the Swiss site is part of an ongoing effort to simplify the company’s manufacturing footprint and supply chain.
Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand Read More »
Positive topline results from a second straight study in generalized anxiety disorder shift the narrative for Definium Therapeutics’ DT120 to commercialization, Jefferies analysts said Monday, while Stifel wrote that the asset is moving towards an FDA submission.
Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’ Read More »
Un estudio reciente aporta datos nuevos y reveladores sobre la genética de los linfomas con reordenamiento de IRF4 en adultos y jóvenes. El linfoma de células B grandes con reordenamiento de IRF4 es una enfermedad poco frecuente que afecta principalmente a niños, …
Nuevos hallazgos sobre la genética de algunos linfomas Read More »
Scholar Rock’s spinal muscular atrophy drug, now to be called Isembyld, was originally rejected in September 2025, when the FDA cited compliance problems at a third-party manufacturer.
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug Read More »
SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.
El 4 de septiembre de 2026, la sonda espacial Parker de la NASA, que partió de la Tierra en 2018, alcanzó la mínima distancia al Sol en su nuevo sobrevuelo de este. Llegó a acercarse a él hasta una distancia de apenas 6,2 millones de kilómetros, igualando el …
Sobrevuelo número 29 del Sol por la sonda espacial Parker Read More »